Adityanarayan Bhatnagar
University Hospital Southampton NHS Foundation Trust · 12 works · 685 citations · h-index 4
Top works
- Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial
- Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial
- CONVERT: An international randomised trial of concurrent chemo-radiotherapy (cCTRT) comparing twice-daily (BD) and once-daily (OD) radiotherapy schedules in patients with limited stage small cell lung cancer (LS-SCLC) and good performance status (PS).
- Trends in surgical and ablative treatment of localised renal cell carcinoma: A review of publication trends over 16 years (2000–2015)
- CONVERT - THE CHALLENGES OF OPENING CENTRES AND RECRUITING PATIENTS TO AN INTERNATIONAL MULTI-CENTRE CHEMO-RADIOTHERAPY TRIAL IN LIMITED-STAGE SMALL CELL LUNG CANCER
- 186 Outcomes following thoracic radiotherapy with 60 Gy in 15 fractions for central and ultracentral malignancies in the Wessex and Thames Valley Network
- Frailty and mortality in a regional UK lung SABR service: can we identify patients for frailty assessment and prehabilitation?
- Real world use of atezolizumab in the management of small cell lung cancer: experience from a UK teaching hospital
- Retrospective review of patterns of recurrence in patients with a histological diagnosis of thymoma
- Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small cell lung cancer in UK clinical practice: are the PACIFIC trial outcomes achievable in the real world?
- Implementing adjuvant immunotherapy following radical chemoradiotherapy for stage III non-small-cell lung cancer in UK clinical practice—Are the PACIFIC trial outcomes achievable in the real world?
- 46 Evaluation of Cardiology Investigations for Oncology Patients on Tyrosine Kinase Inhibitors